OBJECTIVE: To identify chromosomal regions important for progression in clinically organ-confined prostate cancer, as the genetic changes underlying the development and progression of prostate cancer are poorly understood. MATERIALS AND METHODS: Comparative genomic hybridization (CGH) was used to search for DNA sequence copy-number changes in a series of 50 primary organ-confined prostate adenocarcinomas (pT2N0) removed by radical prostatectomy. RESULTS: CGH analysis indicated that 23 (46%) of the primary prostate adenocarcinomas showed chromosome alterations. The percentage of tumours with losses (38%) was higher than with gains (28%). Losses of 13q (24%), 8p (18%), 6q (10%), 16q (8%), 18q (6%) and 5q (6%) and gains of 17q (12%), 20q (12%), 9q (10%), 17p (8%) and 8q (6%) were the most frequent alterations. Amplifications were found at 8q24-qter. Minimal overlapping regions of loss, indicative of the presence of tumour-suppressor genes, were mapped to 13q21.1-q21.3 and 8p21.2, and minimal overlapping regions of gain, indicative of the presence of oncogenes, were found at 9q34.4-qter, 17q25-qter and 20q13.3-qter. There was a significant association between Gleason score and losses and gains (P = 0.003), and an association between chromosomal imbalance and high histological grade (P = 0.008). CONCLUSION: These results suggest that losses or gains of DNA in these regions are important for prostate cancer progression, and document the spectrum of chromosomal alterations in stage pT2N0 of clinically organ-confined prostate cancer.
OBJECTIVE: To identify chromosomal regions important for progression in clinically organ-confined prostate cancer, as the genetic changes underlying the development and progression of prostate cancer are poorly understood. MATERIALS AND METHODS: Comparative genomic hybridization (CGH) was used to search for DNA sequence copy-number changes in a series of 50 primary organ-confined prostate adenocarcinomas (pT2N0) removed by radical prostatectomy. RESULTS: CGH analysis indicated that 23 (46%) of the primary prostate adenocarcinomas showed chromosome alterations. The percentage of tumours with losses (38%) was higher than with gains (28%). Losses of 13q (24%), 8p (18%), 6q (10%), 16q (8%), 18q (6%) and 5q (6%) and gains of 17q (12%), 20q (12%), 9q (10%), 17p (8%) and 8q (6%) were the most frequent alterations. Amplifications were found at 8q24-qter. Minimal overlapping regions of loss, indicative of the presence of tumour-suppressor genes, were mapped to 13q21.1-q21.3 and 8p21.2, and minimal overlapping regions of gain, indicative of the presence of oncogenes, were found at 9q34.4-qter, 17q25-qter and 20q13.3-qter. There was a significant association between Gleason score and losses and gains (P = 0.003), and an association between chromosomal imbalance and high histological grade (P = 0.008). CONCLUSION: These results suggest that losses or gains of DNA in these regions are important for prostate cancer progression, and document the spectrum of chromosomal alterations in stage pT2N0 of clinically organ-confined prostate cancer.
Authors: Gary Loughran; Nollaig C Healy; Patrick A Kiely; Merei Huigsloot; Nancy L Kedersha; Rosemary O'Connor Journal: Mol Biol Cell Date: 2005-01-19 Impact factor: 4.138
Authors: Bassem R Haddad; Lei Gu; Tuomas Mirtti; Ayush Dagvadorj; Paraskevi Vogiatzi; David T Hoang; Renu Bajaj; Benjamin Leiby; Elyse Ellsworth; Shauna Blackmon; Christian Ruiz; Mark Curtis; Paolo Fortina; Adam Ertel; Chengbao Liu; Hallgeir Rui; Tapio Visakorpi; Lukas Bubendorf; Costas D Lallas; Edouard J Trabulsi; Peter McCue; Leonard Gomella; Marja T Nevalainen Journal: Am J Pathol Date: 2013-05-07 Impact factor: 4.307
Authors: Raquel Bermudo; David Abia; Berta Ferrer; Iracema Nayach; Alberto Benguria; Angel Zaballos; Javier del Rey; Rosa Miró; Elías Campo; Carlos Martínez-A; Angel R Ortiz; Pedro L Fernández; Timothy M Thomson Journal: BMC Cancer Date: 2008-10-30 Impact factor: 4.430